drugset / Trial / NCT06512207
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Recruiting
80 enrolled
Jinzhou Medical University
The First Affiliated Hospital of Zhengzhou University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.
Timeline
- Start
- 2023-12-03
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 3.75 mg | — |
| Comparator | Sintilimab | Monoclonal antibody | — | — |